SG11202111717XA - 3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2 - Google Patents
3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2Info
- Publication number
- SG11202111717XA SG11202111717XA SG11202111717XA SG11202111717XA SG11202111717XA SG 11202111717X A SG11202111717X A SG 11202111717XA SG 11202111717X A SG11202111717X A SG 11202111717XA SG 11202111717X A SG11202111717X A SG 11202111717XA SG 11202111717X A SG11202111717X A SG 11202111717XA
- Authority
- SG
- Singapore
- Prior art keywords
- mrgx2
- thiadiazine
- benzo
- inhibitors
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
- C07D285/26—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals
- C07D285/32—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962840344P | 2019-04-29 | 2019-04-29 | |
| PCT/US2020/030305 WO2020223255A1 (en) | 2019-04-29 | 2020-04-28 | 3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202111717XA true SG11202111717XA (en) | 2021-11-29 |
Family
ID=70779887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202111717XA SG11202111717XA (en) | 2019-04-29 | 2020-04-28 | 3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20220119361A1 (es) |
| EP (1) | EP3962901A1 (es) |
| JP (1) | JP2022535672A (es) |
| KR (1) | KR20220012244A (es) |
| CN (1) | CN114072393A (es) |
| AR (1) | AR119728A1 (es) |
| AU (1) | AU2020266529A1 (es) |
| BR (1) | BR112021021508A2 (es) |
| CA (1) | CA3137584A1 (es) |
| CL (1) | CL2021002805A1 (es) |
| CO (1) | CO2021014155A2 (es) |
| CR (1) | CR20210544A (es) |
| DO (1) | DOP2021000223A (es) |
| EC (1) | ECSP21080966A (es) |
| IL (1) | IL287521A (es) |
| JO (1) | JOP20210275A1 (es) |
| MA (1) | MA55804A (es) |
| MX (1) | MX2021013135A (es) |
| PE (1) | PE20220425A1 (es) |
| SG (1) | SG11202111717XA (es) |
| TW (1) | TW202106669A (es) |
| WO (1) | WO2020223255A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI782504B (zh) * | 2020-05-08 | 2022-11-01 | 美商美國禮來大藥廠 | (三氟甲基)嘧啶-2-胺化合物 |
| WO2022152852A1 (en) * | 2021-01-15 | 2022-07-21 | Glaxosmithkline Intellectual Property Development Limited | Antagonists of mrgx2 |
| WO2022152853A1 (en) * | 2021-01-15 | 2022-07-21 | Glaxosmithkline Intellectual Property Development Limited | Antagonists of mrgx2 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| EP1865963A2 (en) * | 2005-02-18 | 2007-12-19 | Acadia Pharmaceuticals Inc. | Triazadibenzoazulene compounds useful for the treatment and prevention of pain and screening methods therefor |
| WO2008052072A2 (en) * | 2006-10-24 | 2008-05-02 | Acadia Pharmaceuticals Inc. | Compounds for the treatment of pain and screening methods therefor |
-
2020
- 2020-04-28 SG SG11202111717XA patent/SG11202111717XA/en unknown
- 2020-04-28 PE PE2021001772A patent/PE20220425A1/es unknown
- 2020-04-28 AU AU2020266529A patent/AU2020266529A1/en active Pending
- 2020-04-28 TW TW109114154A patent/TW202106669A/zh unknown
- 2020-04-28 WO PCT/US2020/030305 patent/WO2020223255A1/en active Application Filing
- 2020-04-28 EP EP20727455.6A patent/EP3962901A1/en active Pending
- 2020-04-28 MX MX2021013135A patent/MX2021013135A/es unknown
- 2020-04-28 CN CN202080047972.XA patent/CN114072393A/zh active Pending
- 2020-04-28 US US17/605,962 patent/US20220119361A1/en active Pending
- 2020-04-28 JO JOP/2021/0275A patent/JOP20210275A1/ar unknown
- 2020-04-28 MA MA055804A patent/MA55804A/fr unknown
- 2020-04-28 JP JP2021564138A patent/JP2022535672A/ja active Pending
- 2020-04-28 BR BR112021021508A patent/BR112021021508A2/pt unknown
- 2020-04-28 CA CA3137584A patent/CA3137584A1/en active Pending
- 2020-04-28 KR KR1020217037664A patent/KR20220012244A/ko unknown
- 2020-04-28 CR CR20210544A patent/CR20210544A/es unknown
- 2020-04-29 AR ARP200101202A patent/AR119728A1/es unknown
-
2021
- 2021-10-22 CO CONC2021/0014155A patent/CO2021014155A2/es unknown
- 2021-10-24 IL IL287521A patent/IL287521A/en unknown
- 2021-10-26 CL CL2021002805A patent/CL2021002805A1/es unknown
- 2021-10-29 DO DO2021000223A patent/DOP2021000223A/es unknown
- 2021-11-15 EC ECSENADI202180966A patent/ECSP21080966A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3137584A1 (en) | 2020-11-05 |
| EP3962901A1 (en) | 2022-03-09 |
| MA55804A (fr) | 2022-04-06 |
| TW202106669A (zh) | 2021-02-16 |
| AR119728A1 (es) | 2022-01-05 |
| BR112021021508A2 (pt) | 2022-03-22 |
| KR20220012244A (ko) | 2022-02-03 |
| CL2021002805A1 (es) | 2022-07-22 |
| WO2020223255A1 (en) | 2020-11-05 |
| CO2021014155A2 (es) | 2021-10-29 |
| ECSP21080966A (es) | 2022-01-31 |
| PE20220425A1 (es) | 2022-03-29 |
| CR20210544A (es) | 2022-03-30 |
| CN114072393A (zh) | 2022-02-18 |
| JOP20210275A1 (ar) | 2023-01-30 |
| IL287521A (en) | 2021-12-01 |
| US20220119361A1 (en) | 2022-04-21 |
| JP2022535672A (ja) | 2022-08-10 |
| MX2021013135A (es) | 2021-11-25 |
| DOP2021000223A (es) | 2022-01-16 |
| AU2020266529A1 (en) | 2021-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287521A (en) | History of 3-amino-h4-benzo[e][4,2,1]thiadiazine 1,1-dioxide as mrgx2 inhibitors | |
| IL285908A (en) | Thiazole derivatives as inhibitors of protein secretion | |
| IL283486A (en) | Thiazole derivatives kill microorganisms | |
| MD3237406T2 (ro) | Derivați ai 5-[(piperazin-1-il)-3-oxo-propil]-imidazolidin-2,4-dionei în calitate de inhibitori ai ADAMTS pentru tratamentul osteoartritei | |
| ZA202204675B (en) | New methylquinazolinone derivatives | |
| IL292182A (en) | History of [4,1]oxazepino[3,2-c]quinolinone as bcl6 inhibitors | |
| IL279939A (en) | History of thiadiazine | |
| IL289197A (en) | History of 2-hydroxycycloalkane-1-carbamoyl | |
| EP3717479C0 (en) | MICROBIOCIDS THIAZOLE DERIVATIVES | |
| EP3833343A4 (en) | HETEROCYCLIC FLAVON DERIVATIVES, COMPOSITIONS AND RELATED METHODS THEREOF | |
| ZA202106024B (en) | Heterocyclic derivatives | |
| EP3752001A4 (en) | SOBETIROMA DERIVATIVES | |
| EP3946288A4 (en) | SUBSTITUTED 5-CYCLOPROPYL-1H-PYRAZOL-3-YL-AMINE DERIVATIVES USED AS SELECTIVE CDK12/13 INHIBITORS | |
| IL291785A (en) | 6,1- Naphthyridine-converted inhibitors of cdk5 | |
| EP3947371C0 (en) | THIAZOLE DERIVATIVES MICROBIOCIDES | |
| RS65294B1 (sr) | Derivati alfa-d-galaktopiranozida | |
| IL276196A (en) | Synthesis of 5-chloro-2-[(3,4,4-trifluoro-3-buten-1-yl)thio]-thiazole | |
| EP3483149A4 (en) | BENZO [D] THIAZOLE DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | |
| EP3683290C0 (en) | LUBRICANTS WITH THIADIAZOLE DERIVATIVES | |
| EP4053114A4 (en) | THIOPHENE DERIVATIVES AS XANTHINE OXIDASE INHIBITORS AND THEIR USE | |
| ZA202101652B (en) | Novel thiazole derivatives and pharmaceutically acceptable salts thereof | |
| WO2015173659A3 (en) | N-(3-oxo-2,3-dihydro-1 h-pyrazol-4-yl)-4,5-dihydronaphtho[2,1 -d]isoxazole-3-carboxamide derivatives and related compounds as smurf-1 inhibitors for the treatment of pulmonary arterial hypertension (pah) | |
| IL310777A (en) | The history of S-alanine is altered | |
| IL304189A (en) | Pyrazolamide derivatives | |
| EP3976601C0 (en) | MICROBIOCIDAL DERIVATIVES |